Duote Biotechnology

Duote Biotech is a clinical-stage biopharmaceutical company headquartered in Hangzhou, China, specializing in the discovery and development of multi-specific antibody therapeutics. The company leverages its proprietary multi-functional antibody platform to engineer next-generation biologics, including T-cell engagers designed to treat hematological malignancies and solid tumors. Its lead programs, DT-001 and DT-002, are bispecific antibodies targeting CD3/CD19 and CD3/BCMA, respectively, with optimized safety profiles to mitigate cytokine release syndrome. Duote Biotech's pipeline also includes novel candidates targeting immune checkpoints and costimulatory pathways like PD-L1 and 4-1BB. Supported by leading venture capital firms such as HighLight Capital and Matrix Partners China, the company aims to address significant unmet needs in the global oncology market. Duote Biotech continues to advance its candidates through clinical trials while expanding its technology platform for diverse therapeutic applications.